Medical Pharmacology: Cancer Chemotherapy Drugs: Anti-Tumor Antibiotics

Doxorubicin clinical use(s):
1. Treatment of multiple myeloma
2. Treatment of lymphomas
3. Both
4. Neither
Clinical use(s) of doxorubicin:
1. Adult sarcomas
2. Pediatric sarcomas
3. Both
4. Neither
Doxorubicin administration is likely beneficial in treating osteogenic, soft-tissue sarcomas and Ewing sarcoma.
1. True
2. False
Concerning toxic effect(s) associated with daunorubicin and doxorubicin:
1. A significant dose-limiting complication is myelosuppression.
2. Reversible stomatitis and mucositis may occur.
3. Doxorubicin administration may induce significant local toxicity in tissue that has been irradiated.
4. A & B
5. B & C
6. A & C
7. A, B & C
The most significant long-term toxicity due to administration of anthracyclines, e.g. daunorubicin and doxorubicin especially is cardiomyopathy.
1. True
2. False
Factor/factors associated with enhanced risk due to anthracycline administration includes/include:
1. Myocardial radiation
2. High-dose cyclophosphamide administration
3. Concomitant administration of trastuzumab.
4. A & B
5. B & C
6. A & C
7. A, B & C
Epirubicin (Ellence) administration may be used as part of combination treatment of breast cancer.
1. True
2. False
This doxorubicin analog (semisynthetic) is only used for intravesicular bladder cancer treatment.
1. Daunorubicin
2. Idarubincin
3. Valrubicin
4. Mitoxantrone
Pegylated liposomal doxorubicin formulation (Doxil) clinical use/uses:
1. Treatment of AIDS-related Kaposi sarcoma
2. Multiple myeloma
3. Ovarian cancer
4. A & B
5. B & C
6. A & C
7. A, B & C
Daunorubicin (cerubidine):
1. Acute lymphoblastic leukemia
2. Acute myelogenous leukemia
3. Both
4. Neither